See what changed recently in IgA Nephropathy research
Your first issue gives you a patient-focused snapshot of recent IgAN research: new treatment studies, clinical trial movement, proteinuria research, and long-term kidney-protection findings.
New treatment updates
Plain-English summaries of recent IgAN research involving therapies such as sparsentan, iptacopan, and other emerging approaches.
Trial and pipeline radar
A simple view of research moving through the IgAN pipeline, written for patients rather than specialists.
Appointment questions
Short prompts to help you turn research updates into better conversations with your care team.
A monthly filter for the IgAN updates worth understanding
Follow new IgAN therapies, trial results, proteinuria research, and pipeline updates without trying to read every paper yourself.
Each summary explains what the study looked at, why it may matter, and what is still uncertain.
Use the monthly issue to prepare for nephrology appointments and ask more informed questions about your care.
For IgA Nephropathy patients who want to stay current between appointments
IgAN Monthly was created for patients and caregivers who know the IgA Nephropathy treatment landscape is changing, but do not have time to track medical journals, trial registries, and dense research papers alone.
- Adults living with IgA Nephropathy or IgAN
- Caregivers helping someone understand new IgAN research
- Patients preparing for nephrology visits every few months
- Anyone who wants clear education without replacing medical care
It’s not medical advice. It’s support for better understanding and better conversations with your care team.
Patient-focused IgAN resources at no additional cost
New Diagnosis Orientation Guide
A practical guide to early IgAN questions, monitoring terms, and the basics many patients wish were explained more clearly.
IgAN Specialist Directory
A curated directory to help patients identify nephrologists and kidney centers with experience in glomerular diseases.
Treatment Landscape Brief
A plain-English overview of current and emerging IgAN treatment categories, including what questions to raise with a doctor.
Research Trial Radar
A regularly updated view of clinical trials and study activity relevant to IgA Nephropathy patients.
Progression Questions Checklist
A short list of questions about monitoring, proteinuria, kidney function, and long-term risk to discuss with your care team.
One simple plan
Gold
Each issue distills recent IgAN research into the 8–10 developments most relevant to patients.
Plain-language summaries you can skim in minutes. No medical background required.
We screen 20+ IgAN research papers and trial updates each month so you can focus on what is worth understanding.
Try It Without Risk
You do not need to commit upfront.
All new subscribers receive a free 30-day trial, with full access to the latest IgAN issue, the archive, and included patient resources.
If it does not help you feel more informed between appointments, you can cancel. No pressure.
98% of subscribers renew after their free trial.
Stay current on IgAN research without trying to track it all alone
Living with IgA Nephropathy is complicated enough. Understanding new research should not require hours of journal reading every month.
Start with one free issue and see whether the summaries help you follow the changing IgAN treatment landscape with more confidence.
If it saves you time, reduces confusion, or helps you ask better questions at your next visit, it is doing its job.
Before you decide
Before you decide, here are answers to a few common questions people have when considering IgAN Monthly.
Why does IgAN need a monthly research newsletter? ⌄
IgA Nephropathy research is moving quickly, especially around new treatments, proteinuria reduction, complement pathways, and long-term kidney protection. Most patients do not have time to read journal articles, trial updates, and specialist discussions between appointments. IgAN Monthly filters the research and explains it in plain English.
What do the new FDA approvals mean for patients? ⌄
Recent IgAN approvals, including sparsentan and iptacopan, show that the treatment landscape is changing. The newsletter does not tell you whether a treatment is right for you. It helps you understand what new studies and approvals are about, what questions they raise, and what may be worth discussing with your nephrologist.
Is this medical advice? ⌄
No. IgAN Monthly is for education and understanding only. It is designed to help you make sense of research and have better conversations with your healthcare team, not replace medical care or professional advice.
Who is this written for? ⌄
The newsletter is written for adults living with IgA Nephropathy, people who search for IgAN updates, and caregivers who want a clearer way to follow research between nephrology appointments.
Can I cancel anytime? ⌄
Yes. Every subscription starts with a free 30-day trial, and you can cancel at any point with no penalties or hoops. If it is not helpful for your situation, you do not need to keep it.